Desvenlafaxine Succinate CAS:386750-22-7

Desvenlafaxine Succinate is a dual serotonin and norepinephrine reuptake inhibitor (SNRI) that was approved for the treatment of major depressive disorder (MDD) in the United States in 2008. In order to improve the efficacy and safety profile of venlafaxine, Wyeth discovered and developed one of the major metabolites of venlafaxine, namely the O-desmethyl metabolite (desvenlafaxine).

Order or Request Quote

Product Detail

Product Tags

Application and Effect

Desvenlafaxine Succinate increases the treatment of serotonin and norepinephrine by inhibiting reuptake mechanisms. More importantly, norvenlafaxine succinate is not a hormonal drug and will become the preferred medication for patients with menstrual syndrome. Desvenlafaxine is also being developed for the treatment of moderate to severe vasomotor symptoms associated with menopause (i.e., hot flashes and night sweats) and is also in phase III clinical trials to study it’s effectiveness in treating fibromyalgia and neuropathic pain.